| Although the evidence from the literature is very preliminary, fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) looks promising in urological cancers. FAPI deserves further investigation as a theranostic agent (labeled with 68Ga for imaging and 177Lu for radioligand therapy) in patients affected by urological cancers. |
| In bladder cancer, FAPI PET seems to enable the detection of metastatic lesions unrevealed at contrast-enhanced computed tomography and deoxy-2-[18F]fluoro-D-glucose PET, in particular small lymph nodes that are frequently missed at primary staging. |
| Less evidence in the literature is available in prostate cancer, with a conceivable synergic role to prostate-specific membrane antigen PET in the detection of primary tumors, and in renal cell carcinoma. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.